Statute Details
- Title: Central Provident Fund (Medisave Account Withdrawals) Regulations 2001
- Type: Subsidiary legislation (regulations made under the Central Provident Fund Act)
- Act Code: CPFA1953-RG17
- Status: Current version (as at 26 Mar 2026)
- Legislative focus: Rules governing withdrawals from a Medisave Account for specified medical and long-term care purposes
- Key Parts: Part 1 (medical treatment withdrawals); Part 2 (long-term care scheme withdrawals)
- Key provisions (by regulation number): Regs 2–26 (Part 1); Regs 27–34 (Part 2); Schedules (including excluded treatments and “severely disabled”)
- Amendment pattern: Frequently amended over time (multiple amendments listed in the legislative timeline, including major updates from 2020 onwards)
What Is This Legislation About?
The Central Provident Fund (Medisave Account Withdrawals) Regulations 2001 (“Medisave Withdrawal Regulations”) sets out the legal framework for when and how a person may withdraw money from their Medisave Account to pay for healthcare. In plain terms, it translates the broad policy of the Central Provident Fund system into detailed, enforceable rules: which types of treatment qualify, who must provide them, what limits apply, and what procedural steps are required to authorise payment.
Medisave is a dedicated savings component intended to help individuals meet medical expenses. However, not every health-related expense is withdrawable. The Regulations therefore define categories of “approved” medical treatment and impose conditions—such as eligibility, provider approval, and caps on withdrawal amounts—to ensure that withdrawals are restricted to intended healthcare purposes and are administered consistently.
The Regulations also address a second policy area: withdrawals for the Long-Term Care (LTC) Scheme. This is distinct from ordinary medical treatment. The LTC provisions specify who may determine eligibility circumstances, the prescribed age and amount rules, the conditions for long-term care, and how excess withdrawals must be repaid.
What Are the Key Provisions?
1) Definitions and the application process for medical treatment (Part 1). Part 1 begins with definitions for the purposes of that Part (regulation 2). It then provides for an application for withdrawal to pay for medical treatment (regulation 3). Practically, this means withdrawals are not automatic: the Board (the Central Provident Fund Board) must be satisfied that the withdrawal falls within the Regulations’ permitted categories and conditions.
2) Limits and “approved” treatment categories. Regulation 4 sets out limits on withdrawal for payment of medical treatment, etc. These limits are crucial for practitioners advising on Medisave claims because they determine the maximum amount that can be withdrawn for a given treatment category (and, in some cases, how multiple categories interact). The Regulations then list specific categories of treatment, each with its own approval and eligibility framework.
For example, the Regulations distinguish between different settings of care: in-patient treatment in approved hospitals (regulation 5), approved community hospitals (regulation 6), approved day hospitals (regulation 7), and approved convalescent hospitals (regulation 8). There are also tailored provisions for in-patient hospices depending on admission date (regulation 9 for admissions before 1 April 2020, and regulation 9AA for admissions on or after 1 April 2020 through an approved IPC provider). This admission-date split is a typical legislative technique used to manage transitional policy changes.
3) Out-patient and specialised treatments. The Regulations do not confine Medisave withdrawals to in-patient care. They include out-patient categories such as out-patient medical treatment from approved home palliative care providers or in approved day hospices (regulation 9A), approved out-patient parenteral nutrition (regulation 9B), and a range of other specified services. The list includes (among others) hepatitis B vaccinations received as in-patient in approved hospitals (regulation 11), surgical treatment to reverse sexual sterilisation and for plastic surgery (regulation 12), and qualifying combined treatment (regulation 12A).
In addition, the Regulations contain provisions for newer or more specialised therapies and services, reflecting ongoing healthcare policy updates. These include out-patient scans (regulation 13A), MIC@Home treatment on or after 1 April 2024 (regulation 13B), out-patient repetitive transcranial magnetic stimulation in approved clinics or approved hospitals (regulation 13C), CTGTP treatment (regulation 13D), and high-cost drug treatment (regulation 13E). There are also provisions for approved chronic illness treatment (regulation 14), approved vaccination (regulation 14A), and approved screening (regulation 14B), with a total limit on withdrawal under regulations 14, 14A and 14B (regulation 14C).
4) Delivery charges, pre-delivery treatment, overseas treatment, and other specific categories. The Regulations address practical cost components and special circumstances. Regulation 15 covers delivery charges, while regulation 16 addresses pre-delivery medical treatment. Regulation 17 provides for overseas medical treatment, which is often a high-risk area for disputes because “approved” status and documentation requirements become more complex when treatment occurs outside Singapore.
Other specified categories include treatment for infertility (regulation 18), renal dialysis treatment (regulation 19), psychiatric treatment (regulation 20), and day surgical treatment (regulation 21). Regulation 21A addresses organ transplantation costs. The Regulations also include a structured framework for specified out-patient treatment (regulation 21B), additional withdrawal for treatment received as out-patient (regulation 21C), and a total limit for withdrawals under regulations 21B and 21C (regulation 21D).
5) Authorisation, reimbursement, and payment mechanics. The Regulations include procedural and administrative rules. Regulation 22 provides for authorisation of withdrawal from future contributions, which is important where the Board may need to fund treatment costs by drawing from future contribution streams rather than existing balances. Regulation 23 addresses reimbursement by another person, which can arise where a third party pays and seeks reimbursement or where the Medisave withdrawal is structured through another payer.
Regulation 24 concerns medical treatment provided to a person other than a dependant, which is a key eligibility constraint: Medisave withdrawals may be restricted depending on the relationship between the account holder and the patient. Regulation 25 provides for payment by the Board, and regulation 25A addresses repayment of moneys withdrawn and paid under section 67D(1) of the Central Provident Fund Act. Finally, regulation 26 allows for revocation of approval of a medical practitioner, which is significant for compliance: if a practitioner’s approval is revoked, future withdrawals tied to that approval may be affected.
6) Long-Term Care Scheme withdrawals (Part 2). Part 2 (regulations 27–34) governs withdrawals from Medisave for the Long-Term Care Scheme. Regulation 27 provides definitions for this Part. Regulation 28 identifies the prescribed person to determine the circumstances for withdrawal—an important governance point because eligibility determinations must be made by the correct authority or role-holder.
Regulation 29 prescribes the amount for purposes of section 16B(1)(a) of the Act. Regulation 30 sets out conditions for long-term care, while regulation 31 prescribes the age for purposes of section 16B(2)(a)(ii) and (b)(ii). Regulation 32 sets limits on withdrawal for long-term care, and regulation 33 provides for the manner of payment. Regulation 34 requires repayment of excess withdrawal, which is a critical enforcement mechanism: if withdrawals exceed what is permitted under the scheme’s rules, the account holder may be required to repay the excess.
7) Schedules: excluded treatments and disability concepts. The Regulations include multiple schedules. The Second Schedule lists Excluded Treatments, which is central to advising clients because it identifies categories that may otherwise appear healthcare-related but are legally excluded from Medisave withdrawal. The Fourth Schedule provides the meaning of “severely disabled”, which likely interacts with eligibility for long-term care withdrawals. The Fifth Schedule sets out the withdrawal limit for the long-term care scheme. Practitioners should treat these schedules as substantive rules, not mere appendices.
How Is This Legislation Structured?
The Regulations are structured into two main Parts. Part 1 (regulations 2–26) covers withdrawals for payment of medical treatment, including in-patient, out-patient, and specialised treatments, as well as administrative rules on authorisation, reimbursement, payment, repayment, and revocation of practitioner approval. Part 2 (regulations 27–34) covers withdrawals for the Long-Term Care Scheme, including definitions, eligibility determination, prescribed amounts and ages, conditions, limits, payment mechanics, and repayment of excess withdrawals.
Beyond the Parts, the Regulations include multiple Schedules. These schedules provide additional legal detail—most notably excluded treatments, definitions (such as “severely disabled”), and withdrawal limits for long-term care. The presence of these schedules indicates that the Regulations operate as a comprehensive compliance document: eligibility is not determined solely by the main regulation text.
Who Does This Legislation Apply To?
The Regulations apply primarily to Medisave account holders and to the healthcare providers and practitioners whose services may be paid for using Medisave withdrawals. In practice, the Board’s authorisation process requires that treatments fall within the Regulations’ approved categories and that providers are “approved” under the relevant framework.
They also apply to persons involved in the administration of withdrawals—such as those who determine long-term care circumstances (Part 2), and any third parties who may be involved in reimbursement or payment arrangements. Where the Regulations restrict withdrawals for treatment provided to persons other than dependants, the account holder’s eligibility and the patient’s relationship status become legally relevant.
Why Is This Legislation Important?
For practitioners, the Medisave Withdrawal Regulations are important because they govern a high-volume, high-sensitivity area of healthcare funding: whether a particular treatment cost can be paid from a person’s Medisave account. Disputes often arise around whether a treatment is within an approved category, whether the provider is approved, whether the treatment setting qualifies (in-patient versus out-patient), and whether the withdrawal amount exceeds statutory limits.
The Regulations’ detailed categorisation—covering everything from specific vaccination and screening rules to newer therapies such as MIC@Home and high-cost drug treatment—means that legal advice must be treatment-specific. A generic “medical expense” argument is unlikely to succeed if the treatment is excluded by the Second Schedule or falls outside the relevant regulation category.
Enforcement is also embedded in the Regulations. Repayment provisions (including repayment of excess long-term care withdrawals and repayment under the Act’s section 67D(1) framework) create financial consequences for non-compliant or over-withdrawn claims. Additionally, the Board’s ability to revoke practitioner approval underscores that compliance is dynamic: eligibility can change if approvals are withdrawn.
Related Legislation
- Central Provident Fund Act (including provisions referenced in the Regulations, such as section 16B and section 67D(1))
- Central Provident Fund (Medisave Account Withdrawals) Regulations 2001 amendments and related subsidiary instruments (as reflected in the legislative timeline)
Source Documents
This article provides an overview of the Central Provident Fund (Medisave Account Withdrawals) Regulations 2001 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.